Also Known As: Nirmatrelvir/Ritonavir, Paxlovid

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid (/pæksˈlvɪd/ paks-LOH-vihd or /ˈpæksləvɪd/ PAKS-lə-vihd), is a co-packaged oral medication used as a treatment for COVID-19.[7][9][14] It contains the antiviral medications nirmatrelvir and ritonavir.[7][9]

In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19.[11][15] It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19.[10] It was approved in the United Kingdom later that month,[16] and in the European Union and Canada in January 2022.[12][17][18]

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Complete a survey on Nirmatrelvir/Ritonavir to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.